PMID- 30144017
OWN - NLM
STAT- MEDLINE
DCOM- 20190528
LR  - 20190528
IS  - 1179-187X (Electronic)
IS  - 1175-3277 (Linking)
VI  - 18
IP  - 6
DP  - 2018 Dec
TI  - Biomarkers of Thrombosis in ST-Segment Elevation Myocardial Infarction: A 
      Substudy of the ATOLL Trial Comparing Enoxaparin Versus Unfractionated Heparin.
PG  - 503-511
LID - 10.1007/s40256-018-0294-z [doi]
AB  - BACKGROUND: The aim was to compare the peri-procedural biomarkers of coagulation 
      and platelet activation in patients randomly allocated to intravenous enoxaparin 
      or unfractionated heparin (UFH) in the ATOLL randomized trial (NCT00718471). 
      METHODS AND RESULTS: A total of 129 patients (n = 58 enoxaparin and n = 71 UFH) 
      admitted for ST-segment elevation myocardial infarction (STEMI) treated by 
      percutaneous coronary intervention (PCI) were included in this substudy of the 
      ATOLL trial. Activated partial thromboplastin time ratio, anti-Xa activity, von 
      Willebrand factor antigen, prothrombin fragment 1 + 2 (F1 + 2), 
      thrombin-antithrombin complex (TAT), tissue factor pathway inhibitor and soluble 
      CD40 ligand were measured at sheath insertion (T1) and at the end of the PCI (T2) 
      and correlated with 1-month clinical outcomes. Target anticoagulation levels at 
      T2 were more readily achieved in patients receiving enoxaparin compared to those 
      receiving UFH (80.3 vs 18.2%, p < 0.0001). Increased levels of F1 + 2 and TAT 
      measured at T2 were associated with the incidence of the composite ischemic 
      endpoint (p = 0.04 and p = 0.03) and all-cause mortality (p < 0.0001 and 
      p = 0.002). Release of F1 + 2 between T1 and T2 also predicted the composite 
      ischemic endpoint (312 +/- 513 vs 37 +/- 292, p = 0.04) and net clinical outcome 
      (185 +/- 405 vs 3.2 +/- 278, p = 0.03). CONCLUSIONS: During primary PCI, enoxaparin 
      achieved therapeutic levels more frequently than UFH. Higher level of thrombin 
      generation measured at the end of the PCI procedure was associated with more 
      frequent ischemic events.
FAU - Silvain, Johanne
AU  - Silvain J
AD  - Sorbonne Universite-Univ Paris 06 (UPMC), ACTION Study Group, INSERM, UMRS 1166, 
      Institut de Cardiologie, Hopital Pitie-Salpetriere (AP-HP), 47-83 bld de 
      l'Hopital, 75013, Paris, France.
AD  - Service mobile d'urgence et de reanimation (SMUR), Pitie-Salpetriere Hospital 
      (AP-HP), Universite Paris 6, Paris, France.
FAU - O'Connor, Stephen A
AU  - O'Connor SA
AD  - Sorbonne Universite-Univ Paris 06 (UPMC), ACTION Study Group, INSERM, UMRS 1166, 
      Institut de Cardiologie, Hopital Pitie-Salpetriere (AP-HP), 47-83 bld de 
      l'Hopital, 75013, Paris, France.
AD  - Service mobile d'urgence et de reanimation (SMUR), Pitie-Salpetriere Hospital 
      (AP-HP), Universite Paris 6, Paris, France.
FAU - Yan, Yan
AU  - Yan Y
AD  - Emergency and Critical Care Center, Beijing Anzhen Hospital, Capital Medical 
      University, Beijing, 100029, China.
AD  - Service mobile d'urgence et de reanimation (SMUR), Pitie-Salpetriere Hospital 
      (AP-HP), Universite Paris 6, Paris, France.
FAU - Kerneis, Mathieu
AU  - Kerneis M
AD  - Sorbonne Universite-Univ Paris 06 (UPMC), ACTION Study Group, INSERM, UMRS 1166, 
      Institut de Cardiologie, Hopital Pitie-Salpetriere (AP-HP), 47-83 bld de 
      l'Hopital, 75013, Paris, France.
AD  - Service mobile d'urgence et de reanimation (SMUR), Pitie-Salpetriere Hospital 
      (AP-HP), Universite Paris 6, Paris, France.
FAU - Hauguel-Moreau, Marie
AU  - Hauguel-Moreau M
AD  - Sorbonne Universite-Univ Paris 06 (UPMC), ACTION Study Group, INSERM, UMRS 1166, 
      Institut de Cardiologie, Hopital Pitie-Salpetriere (AP-HP), 47-83 bld de 
      l'Hopital, 75013, Paris, France.
AD  - Service mobile d'urgence et de reanimation (SMUR), Pitie-Salpetriere Hospital 
      (AP-HP), Universite Paris 6, Paris, France.
FAU - Zeitouni, Michel
AU  - Zeitouni M
AD  - Sorbonne Universite-Univ Paris 06 (UPMC), ACTION Study Group, INSERM, UMRS 1166, 
      Institut de Cardiologie, Hopital Pitie-Salpetriere (AP-HP), 47-83 bld de 
      l'Hopital, 75013, Paris, France.
AD  - Service mobile d'urgence et de reanimation (SMUR), Pitie-Salpetriere Hospital 
      (AP-HP), Universite Paris 6, Paris, France.
FAU - Overtchouk, Pavel
AU  - Overtchouk P
AD  - Sorbonne Universite-Univ Paris 06 (UPMC), ACTION Study Group, INSERM, UMRS 1166, 
      Institut de Cardiologie, Hopital Pitie-Salpetriere (AP-HP), 47-83 bld de 
      l'Hopital, 75013, Paris, France.
AD  - Service mobile d'urgence et de reanimation (SMUR), Pitie-Salpetriere Hospital 
      (AP-HP), Universite Paris 6, Paris, France.
FAU - Ankri, Annick
AU  - Ankri A
AD  - Service d'Hematologie Biologique, Pitie-Salpetriere Hospital (AP-HP), Universite 
      Paris 6, Paris, France.
AD  - Service mobile d'urgence et de reanimation (SMUR), Pitie-Salpetriere Hospital 
      (AP-HP), Universite Paris 6, Paris, France.
FAU - Brugier, Delphine
AU  - Brugier D
AD  - Sorbonne Universite-Univ Paris 06 (UPMC), ACTION Study Group, INSERM, UMRS 1166, 
      Institut de Cardiologie, Hopital Pitie-Salpetriere (AP-HP), 47-83 bld de 
      l'Hopital, 75013, Paris, France.
AD  - Service mobile d'urgence et de reanimation (SMUR), Pitie-Salpetriere Hospital 
      (AP-HP), Universite Paris 6, Paris, France.
FAU - Vicaut, Eric
AU  - Vicaut E
AD  - Methodology and Statistical Unit, Centre Hospitalier Universitaire Lariboisiere 
      (ACTION Group, AP-HP, Universite Paris 7), Paris, France.
AD  - Service mobile d'urgence et de reanimation (SMUR), Pitie-Salpetriere Hospital 
      (AP-HP), Universite Paris 6, Paris, France.
FAU - Ecollan, Patrick
AU  - Ecollan P
AD  - Methodology and Statistical Unit, Centre Hospitalier Universitaire Lariboisiere 
      (ACTION Group, AP-HP, Universite Paris 7), Paris, France.
AD  - Service mobile d'urgence et de reanimation (SMUR), Pitie-Salpetriere Hospital 
      (AP-HP), Universite Paris 6, Paris, France.
FAU - Galier, Sophie
AU  - Galier S
AD  - Sorbonne Universite-Univ Paris 06 (UPMC), ACTION Study Group, INSERM, UMRS 1166, 
      Institut de Cardiologie, Hopital Pitie-Salpetriere (AP-HP), 47-83 bld de 
      l'Hopital, 75013, Paris, France.
AD  - Service mobile d'urgence et de reanimation (SMUR), Pitie-Salpetriere Hospital 
      (AP-HP), Universite Paris 6, Paris, France.
FAU - Collet, Jean-Philippe
AU  - Collet JP
AD  - Sorbonne Universite-Univ Paris 06 (UPMC), ACTION Study Group, INSERM, UMRS 1166, 
      Institut de Cardiologie, Hopital Pitie-Salpetriere (AP-HP), 47-83 bld de 
      l'Hopital, 75013, Paris, France.
AD  - Service mobile d'urgence et de reanimation (SMUR), Pitie-Salpetriere Hospital 
      (AP-HP), Universite Paris 6, Paris, France.
FAU - Montalescot, Gilles
AU  - Montalescot G
AD  - Sorbonne Universite-Univ Paris 06 (UPMC), ACTION Study Group, INSERM, UMRS 1166, 
      Institut de Cardiologie, Hopital Pitie-Salpetriere (AP-HP), 47-83 bld de 
      l'Hopital, 75013, Paris, France. gilles.montalescot@psl.aphp.fr.
AD  - Service mobile d'urgence et de reanimation (SMUR), Pitie-Salpetriere Hospital 
      (AP-HP), Universite Paris 6, Paris, France. gilles.montalescot@psl.aphp.fr.
CN  - ATOLL Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT00718471
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - New Zealand
TA  - Am J Cardiovasc Drugs
JT  - American journal of cardiovascular drugs : drugs, devices, and other 
      interventions
JID - 100967755
RN  - 0 (Anticoagulants)
RN  - 0 (Biomarkers)
RN  - 0 (Enoxaparin)
RN  - 0 (Lipoproteins)
RN  - 0 (Von Willebrand antigen)
RN  - 0 (antithrombin III-protease complex)
RN  - 0 (lipoprotein-associated coagulation inhibitor)
RN  - 0 (von Willebrand Factor)
RN  - 147205-72-9 (CD40 Ligand)
RN  - 9000-94-6 (Antithrombin III)
RN  - 9001-26-7 (Prothrombin)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.- (Peptide Hydrolases)
RN  - EC 3.4.21.6 (Factor Xa)
SB  - IM
MH  - Aged
MH  - Anticoagulants/administration & dosage/adverse effects/*therapeutic use
MH  - Antithrombin III
MH  - Biomarkers
MH  - CD40 Ligand/blood
MH  - Enoxaparin/administration & dosage/adverse effects/*therapeutic use
MH  - Factor Xa/analysis
MH  - Female
MH  - Heparin/administration & dosage/adverse effects/*therapeutic use
MH  - Humans
MH  - Lipoproteins/analysis
MH  - Male
MH  - Middle Aged
MH  - Partial Thromboplastin Time
MH  - Peptide Hydrolases/blood
MH  - Percutaneous Coronary Intervention/*methods
MH  - Prothrombin/analysis
MH  - ST Elevation Myocardial Infarction/*blood/mortality/*surgery
MH  - von Willebrand Factor/analysis
FIR - Montalescot, G
IR  - Montalescot G
FIR - Zeymer, U
IR  - Zeymer U
FIR - Silvain, J
IR  - Silvain J
FIR - Boulanger, B
IR  - Boulanger B
FIR - Cohen, M
IR  - Cohen M
FIR - Goldstein, P
IR  - Goldstein P
FIR - Ecollan, P
IR  - Ecollan P
FIR - Combes, X
IR  - Combes X
FIR - Huber, K
IR  - Huber K
FIR - Pollack, C Jr
IR  - Pollack C Jr
FIR - Benezet, J F
IR  - Benezet JF
FIR - Stibbe, O
IR  - Stibbe O
FIR - Filippi, E
IR  - Filippi E
FIR - Teiger, E
IR  - Teiger E
FIR - Cayla, G
IR  - Cayla G
FIR - Elhadad, S
IR  - Elhadad S
FIR - Adnet, F
IR  - Adnet F
FIR - Chouihed, T
IR  - Chouihed T
FIR - Gallula, S
IR  - Gallula S
FIR - Greffet, A
IR  - Greffet A
FIR - Aout, M
IR  - Aout M
FIR - Collet, J P
IR  - Collet JP
FIR - Vicaut, E
IR  - Vicaut E
EDAT- 2018/08/26 06:00
MHDA- 2019/05/29 06:00
CRDT- 2018/08/26 06:00
PHST- 2018/08/26 06:00 [pubmed]
PHST- 2019/05/29 06:00 [medline]
PHST- 2018/08/26 06:00 [entrez]
AID - 10.1007/s40256-018-0294-z [pii]
AID - 10.1007/s40256-018-0294-z [doi]
PST - ppublish
SO  - Am J Cardiovasc Drugs. 2018 Dec;18(6):503-511. doi: 10.1007/s40256-018-0294-z.